Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
During therapy with second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia, a number of patients demonstrate non-hematological toxicity of various degrees. The article contains review of references about second generation tyrosine kinase inhibitors effect on the frequ...
Saved in:
Main Author: | O. Y. Vinogradova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-10-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/154 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic myeloid leukemia — before and after imatinib (Third part)
by: E. G. Lomaia, et al.
Published: (2022-11-01) -
The Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid Leukemia
by: S. I. Kutsev, et al.
Published: (2010-06-01) -
Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
by: Chen J, et al.
Published: (2025-07-01) -
Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01) -
Molecular genetics monitoring of tyrosine kinase inhibitor therapy for chronic myeloid leukemia
by: S. I. Kutsev, et al.
Published: (2022-11-01)